Sionna Therapeutics Announces Topline Data From Two Nucleotide Binding Domain 1 Stabilizer Programs; Precision CF Trial Did Not Meet Its Key Activity Endpoint; Phase 1 trial of SION-451 Achieved Safety, Tolerability And Pharmacokinetic Objectives
Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today reported topline data from two nucleotide binding domain 1
Sionna's CF medicine test didn't work as hoped, but their early safety test went well. When a company has some good news and some bad news mixed together, it's worth watching what happens next to see if they can fix the problem.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.